Aptar appoints Julie Xing to its Board of Directors

With over 20 years of experience in pharmaceutical, medtech, digital health, biotech, and diagnosis, Julie’s leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple global positions, Julie is recognized as a highly engaging multicultural leader skilled in fluidly partnering with cross-functional teams to deliver results.

Since 2022, Julie has served as executive chair of the board of directors at Mundipharma, China. Mundipharma is a global pharmaceutical leader. Prior to that, Julie held the position of Global Senior Vice President, President of Greater China for Envista Holdings Corporation. Julie’s breadth of experience also includes numerous leadership roles at Eli Lilly and Company, including senior director, global new product planning and payer marketing, pricing, reimbursement and access of Lilly Diabetics and vice president, corporate and government affairs and market access and vice president of Lilly China Oncology, while based in Shanghai. Before Eli Lilly, Julie was vice president and general manager of Asia Pacific and Japan Operations at Panomics and Affymetrix, which was acquired by Thermo Fisher Scientific.

In addition, she has served as a board advisor on the Board of Directors for Mars, a global manufacturer of confectionery, pet food and provider of animal care services, since 2019. Julie holds a Ph.D. in Biology from the Hong Kong University of Science and Technology.

“We are pleased to welcome Julie Xing to our Board of Directors. Julie’s board leadership acumen, along with her in-depth knowledge of the pharmaceutical market and the Asia region, makes her a valuable addition to Aptar’s Board of Directors,” said Stephan B. Tanda, president, and chief executive officer, Aptar.

Julie Xing said, “Aptar is an industry leader with a deep portfolio of products and services that spans many different and attractive pharmaceutical and consumer end markets. I am excited to join Aptar’s Board of Directors to build upon the Company’s more than 75-year history of developing innovative products that millions of people around the world use every day.”

George Fotiades, chairman - Board of Directors, Aptar, stated, “We look forward to welcoming Julie to our highly talented, diverse, and multicultural Board of Directors. With 45% of our Board consisting of women and 27% of our Board comprised of persons of color, we are proud to be a leading company for greater diversity and gender equality on corporate boards.”